Abstract
The efficacy of recombinant interferon-alpha (rIFN α), on natural killer (NK) cell cytotoxic activity, CD3+, CD4+, CD8+, CD56+, HLA−DR+ lymphocyte counts, anti-acetylcholine receptor antibody (AChR Ab) levels, single fibre electromyography findings (SFEMG) and clinical course were evaluated in patients with myasthenia gravis (MG). During the IFN α treatment (3 mu, subcutaneous, 3 times a week), NK cell cytotoxicity and CD4+/8+ ratio increased, NK cell count remarkably decreased, and no significant clinical or SFEMG changes were observed. This preliminary open study in MG patients has demonstrated enhanced NK activity per unit NK cell after IFN α therapy. Although lymphocyte phenotypes and NK function approached normal levels during therapy, a higher dose of IFN α may be required for a significant clinical response. It has been also concluded that 6 months of IFN α therapy seems to be safe in MG, though in patients with malignancy, IFN α may cause increased autoimmunity, AChR positivity and MG.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
